Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus ILOSONE.
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus ILOSONE.
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin ethylsuccinate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation. Sulfisoxazole acetyl is a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
Erythromycin ethylsuccinate (400 mg) and sulfisoxazole acetyl (600 mg) per 5 mL suspension: 2-3 teaspoonfuls (10-15 mL) orally every 6 hours for 10-14 days. Maximum daily dose: 6 g sulfisoxazole.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
Erythromycin: terminal half-life of 1.4-2.0 hours in adults; prolonged to 4-6 hours in anuria. Sulfisoxazole: half-life 4.5-7 hours in adults; increased in renal impairment. The combination's clinical context warrants dosing interval adjustments in renal dysfunction.
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Erythromycin ethylsuccinate is primarily excreted in bile (up to 80% as unchanged drug), with about 12-15% eliminated renally. Sulfisoxazole acetyl is renally excreted, with approximately 85% of the dose appearing in urine as acetylated and deacetylated metabolites. Fecal elimination accounts for less than 10% of sulfisoxazole.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic